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Abstract: There is growing interest in anal cancer screening strategies. However, cytological/molecular
evaluation of anal samples is challenging. We aimed to determine the feasibility of detecting, in anal
liquid-based cytologies, the expression of biomarkers involved in the cell cycle disturbance elicited
by human papillomavirus (HPV). The accuracy of this approach in the identification of high-grade
squamous intraepithelial lesions/anal intraepithelial neoplasia grade2–3 (HSIL/AIN2–3) was also
evaluated. 215 anal cytologies from men having sex with men living with human immunodeficiency
virus were evaluated. Patients showing concordant cytological and anoscopy-directed biopsy
diagnosis were selected: 70 with negative cytology and HPV test, 70 with low-grade SIL (LSIL/AIN1)
cytology and biopsy, and 75 with cytology and biopsy of HSIL/AIN2–3. CDKN2A/p16, MKI67 and
TOP2A mRNA expression was analyzed. HPV detection was performed with Xpert HPV Assay
(Cepheid, Sunnyvale, CA, USA). HSIL/AIN2–3 showed higher expression for the biomarkers than
LSIL/AIN1 or negative samples. The specificity for HSIL/AIN2–3 detection for a sensitivity established
at 70% was 44.7% (95%confidence interval [CI] 36.5–53.2) for TOP2A and MKI67 and 54.5% (95%CI
46.0–62.8%) for CDKN2A/p16. mRNA detection of cell biomarkers in anal liquid-based cytology is
feasible. Further studies are warranted to confirm if strategies based on mRNA detection have any
role in anal cancer screening.
Keywords: anal cancer; anal cytology; HPV; mRNA; biomarkers
1. Introduction
Although anal cancer is infrequent in the general population, over the past decade its incidence
and mortality have increased by about 2.2% and 2.9% per year, respectively [1]. The incidence
of anal cancer is mainly concentrated in some specific, well-defined groups of patients, including
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men who have sex with men, particularly those living with human immunodeficiency virus (HIV),
other non-HIV-related immunosuppressed populations, and women with human papillomavirus
(HPV)-associated disease [2–5]. Despite these groups have different anal cancer risk, overall,
the incidence of this neoplasia exceeds that of cervical cancer, the overall most frequent HPV-associated
cancer [6]. Thus, there is a growing interest in developing screening and surveillance strategies for
anal cancer, targeting these high-risk populations.
Many analogies have been recognized between anal and cervical cancer. Indeed, the common
etiology of these two cancers (HPV) has prompted the use of the screening strategies performed for
cervical cancer to prevent anal cancer. However, there are important differences between these two
diseases that need to be addressed in the populations at risk [2–4]: the diverse evolution of the two
diseases in the absence of treatment (natural history) [7,8] and the results in terms of disease control of
the clinical management of the two premalignant lesions (clinical outcomes) [1].
Although scant data is available, the screening strategies currently available for the prevention of
anal cancer and its precursor, high-grade squamous intraepithelial lesion/anal intraepithelial neoplasia
grade 2–3 (HSIL/AIN2–3) are far from ideal. As a result, the proposed screening recommendations
are mainly based on expert opinions. Anal cytology has shown a low sensitivity and specificity for
HSIL/AIN2–3 detection [1], whereas HPV testing provides an excellent sensitivity but has an extremely
poor specificity in high-risk populations [9–11].
The detection of host-cell mRNA biomarkers involved in DNA replication and cell cycle
progression, such as TOP2A, and other HPV-induced cell molecules involved in cell cycle control, such
as MKi67 or p16 (CDKN2A), has proved to be feasible in cervical samples preserved in liquid-based
cytology media [12]. Moreover, previous studies have shown that these biomarkers are potentially
useful in the detection of intraepithelial lesions of the uterine cervix. Preliminary results suggest that
this strategy might be useful for the detection of cervical HSIL/CIN2–3 [12]. However, there are no
data on the use of mRNA-based techniques to detect these host-cell biomarkers in anal liquid-based
cytology samples. The large size of the area to be sampled due to the anatomical complexity of the anal
canal, the keratinizing nature of the epithelium which frequently causes the exfoliation of a limited
number of viable cells, together with the presence of contaminating fecal material [13–15] result in
samples that are technically challenging to analyze. Consequently, few studies have been performed
using molecular methods. [16,17]
In the present study we aimed to determine the feasibility of the detection of the mRNA of three
HPV-associated biomarkers (TOP2A, MKi67 and CDKN2A) in anal samples preserved in liquid-based
cytology and to evaluate whether this approach provides valuable information for the detection of
HSIL/AIN2–3.
2. Materials and Methods
2.1. Study Design and Case Selection
For this cross-sectional study, anal cytology samples, collected in the Anal Cancer Prevention Unit
from January to December 2016 from men who have sex with men living with HIV, were retrieved
from the Department of Pathology of the Hospital Clinic. All patients had been referred to the Anal
Cancer Prevention Unit from the HIV Unit of our center. All were under highly active antiretroviral
therapy (HAART) and had an undetectable viral load and CD4 counts > 400 cells/mL. Patients with
anal sample fulfilling the following inclusion criteria were considered eligible for study: (1) anal
liquid-based-cytology sample with adequate material for conventional cytology and HPV testing; (2) in
cases with abnormal cytology and/or positive HPV test, a high-resolution anoscopy with at least one
directed biopsy [18].
For this validation study we considered the following three diagnostic categories as concordant
results: (a) negative (control group): normal anal cytology result and negative HPV test; (b) LSIL: anal
cytology result of LSIL and biopsy confirming LSIL/AIN1; and (c) HSIL/AIN: anal cytology result of
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HSIL and biopsy confirming HSIL/AIN2–3 [12,19]. The following were considered as exclusion criteria:
(1) previous history or histological diagnosis of anal cancer in the simultaneous biopsy; (2) previous
treatment for HSIL/AIN2–3 performed within the previous 3 years; and (3) previous HPV vaccination.
A total of 215 patients who fulfilled the inclusion criteria were included in the study: 70 with
a negative result (control group), 70 with LSIL/AIN1 (LSIL group) and 75 with HSIL/AIN2–3 (HSIL
group). The study was approved by the institutional ethical review board of Hospital Clínic of
Barcelona (2.26/01/2018, 16 February 2018) and all patients provided signed informed consent.
2.2. Cytology Sampling, High-Resulution Anoscopy and Biopsy
The anal sample was collected using a moistened Dacron swab, which was transferred to
PreservCyt solution (Hologic, Marlborough, MA, USA). In all patients with abnormal cytology a
high-resolution anoscopy was performed. Prior to the anoscopy, a digital anorectal examination was
carried out to rule out abnormalities suggestive of anal cancer. The high-resolution anoscopy was
performed using an Olympus Evis Exera II CV-180 anoscope (Olympus, Barcelona, Spain). Anal
evaluation was carefully performed with 5% acetic acid, and iodine-based solution was used to stain
the anal canal and to highlight areas of abnormal epithelium. On the detection of suspicious lesions,
a high-resolution anoscopy directed biopsy was obtained.
2.3. Liquid-Based Cytology, Histological Diagnosis and HPV Testing
The first part of the anal sample was used for cytological analysis. The residual material was used
first for HPV testing and thereafter for RNA isolation.
Thin-layer cytology slides were prepared using the Thinprep T2000 slide processor (Hologic)
and stained using the Papanicolaou method. Cytology slides were evaluated by a cytotechnologist
(L.M.) and reviewed by a citopathologist (L.R.) using the revised Bethesda criteria [20]. Subsequently,
liquid-based cytology samples were used for mRNA evaluation.
All histological samples were fixed in 10% formalin-fixed and embedded in paraffin following
routine procedures. Four-µm sections were routinely stained with hematoxylin and eosin (HandE).
All the histological samples were carefully reviewed by a pathologist (J.O.) with experience in
HPV-related lesions to confirm the presence or absence of SIL/AIN and its grade. The histological
diagnoses were established using pure morphologic criteria based on the HandE-stained sections,
with no knowledge of HPV status or the cytology result [21]. Biopsy specimens were classified as
normal, LSIL/AIN1, and HSIL/AIN2–3 according to the lower anogenital squamous terminology
(LAST) criteria [22]. p16 immunohistochemical staining was performed in all the cervical samples
obtained. A positive block staining for p16 in the dysplastic area was required for the diagnosis of
HSIL/AIN2–3 [23].
HPV detection was performed using the Xpert HPV Assay (Xpert; Cepheid, Sunnyvale, CA)
in the material collected in liquid-based media (PreservCyt) [24]. The Xpert HPV Assay (Cepheid,
Inc, Sunnyvale, CA) is a quantitative polymerase chain reaction (qPCR) assay that uses disposable
cartridges able to detect 14 types of high-risk HPV DNA (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, 68). Xpert HPV assay results offer partial genotyping including HPV 16, HPV 18 and/or 45,
and high-risk HPV other than 16, 18 or 45.
2.4. RNA Isolation, Reverse Transcriptase PCR (RT-PCR) and qPCR
Once the cytological exam and the HPV testing had been performed, 5mL of the cell suspension
was centrifuged at 3000G for 5 min, and the cell pellet was mixed with 700 µL QIAzol lysis reagent
(Qiagen, Hilden, Germany). Total RNA was extracted using the RNeasy RNA extraction kit (Qiagen),
according to the manufacturer’s protocol. Sample preparation was carried out with the highest
measures of quality control to avoid contamination and cross-contamination. RNA concentrations were
measured with a Nano-Drop instrument (Thermo Scientific, Wilmington, DE, USA). The total RNA
yield varied between 0.5 and 64.3 mg, reflecting the variability of the cell numbers in the specimens.
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Reverse transcription (RT) was performed starting with 10 µL of total RNA in a 20 µL reaction
volume using random hexamers and the high capacity cDNA RT-kit from Applied Biosystems
(Foster City, CA, USA) according to the manufacturer’s protocol. To exclude DNA contamination a
reaction without RT was run in parallel with each specimen, as described previously [12].
All PCRs were performed in triplicate at a reaction volume of 25 µL containing 5 µL of cDNA
diluted at 1:5 and mixed with Taqman Universal PCR MasterMix (Applied Biosystems). The following
protocol was used for all assays: denaturation (10 min at 95 ◦C) and amplification (15 sec at 95 ◦C,
1 min at 60 ◦C) repeated for 40 cycles. The expression of CDKN2A/p16, MKI67 and TOP2A, was
analyzed. Beta glucuronidase (GUSB) and cGMP-dependent protein kinase 1 (PKG1) were selected as
reference genes for quality control of the RNA. This combination of reference genes showed a high
stability in expression between groups of normal samples versus HSIL samples. The SiHa cell line was
selected as a reference for RNA normalization.
The number of cycles required for the signal to cross the threshold (cycle threshold [Ct] value) for
target genes was set at 35 cycles [12]. For the reference gene PRKG1, a Ct value above 35 cycles indicates
poor RNA quality. Samples above these Ct values were therefore considered invalid and excluded from
the analysis. The primer and probe sequences used in the qPCR are shown in Table 1 [12]. All probes
were FAM-labeled, and all reactions were run in singleplex.
Table 1. Primers and probes used to detect the mRNA expression of the biomarkers analyzed in
the study.
Target Gene Source
CDKN2A F: 5′-CATAGATGCCGCGGAAGGT-3′ Life Technologies
R: 5′-CCCGAGGTTTCTCAGAGCCT-3′
P: FAM-CCTCAGACATCCCCGATTGAAAGAACC-TAMRA
MKI67 MKI67 (Hs010332443_m1 Life Technologies
TOP2A TOP2A (Hs03063307_m1) Life Technologies
GUSB GUSB (Hs99999908_m1) Life Technologies
PGK1 PGK1 (Hs99999906_m1) Life Technologies
2.5. Data Analysis
The data were analyzed with the SPSS program (Version 24.0). The analysis of variance test was
used to compare quantitative variables between the different categories. The χ2 test was used for
comparisons between categorical variables. A p ≤ 0.05 was considered statistically significant.
All data related to expression are presented as ∆∆Ct, which was calculated as (the Ct value of
the target gene − the Ct value of the reference gene) − (the Ct value of the target gene for SiHa −
the Ct value of the reference gene for SiHa) [25,26]. SiHa cells were used as reference, as these are
HPV16-immortalized squamous cells, considered as a model for HPV-induced alterations associated
with cell immortalization. [27,28] High ∆∆Ct values correspond to low expression of a marker, whereas
a low ∆∆Ct corresponds to a high expression of that marker. The level of significance between target
gene expression in normal samples and HSIL/AIN2–3 samples was analyzed using ROC analysis.
Using ROC curves, we obtained the specificity and ∆∆Ct cut off value of the different biomarkers for a
sensitivity of 70%, 80% and 90%.
3. Results
One-hundred and ninety-nine out of 215 (92.6%) samples were considered adequate for analysis,
and only 16 could not be evaluated due to low expression of the reference genes and/or low RNA
yield. Of the 199 samples finally included in the study 66 (33.2%) were normal, 66 (33.2%) LSIL, and 67
(33.7%) HSIL. No differences in terms of adequacy for analysis were observed between the three groups
of samples (66/70 [94.3%] normal, 66/70 [94.3%] LSIL, and 67/75 [89.3%] HSIL, p = 0.419).
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Table 2 and Figure 1 show the mRNA levels of TOP2A, MKI67 and CDKN2A/p16 expressed as
∆∆Ct [(Ct target-Ct reference sample) − (Ct SiHa-Ct reference SiHa)] in each diagnostic group. The
mRNA expression was significantly higher in HSIL compared with LSIL and negative samples for
the three biomarkers: TOP2A (p = 0.043 and p = 0.030, respectively), MKI67 (p = 0.011 and p < 0.001,
respectively) and CDKN2A/p16 (p = 0.011 and p < 0.001, respectively). CDKN2A/p16 expression in
LSIL specimens was also significantly higher compared with negative samples (p = 0.030), but no
differences were observed between LSIL and negative samples for the other two biomarkers.
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and negative high-risk human papillomavirus [HPV] test); (b) low-grade squamous intraepithelial 
lesion (LSIL) (Pap test result of LSIL and biopsy showing anal intraepithelial neoplasia grade 1 
[LSIL/AIN1]); and (c) high-grade squamous intraepithelial lesion (HSIL) (patients with Pap test result 
of HSIL and biopsy confirming HSIL/AIN2–3). The values shown are expressed as ΔΔCt [(cycle 
threshold target-cycle threshold reference sample) − (cycle threshold SiHa-cycle threshold reference 
SiHa)]. The black line within the box represents the median; the whiskers represent the minimum and 
maximum values that lie within 1.5 interquartile ranges from the end of the box. Values outside this 
range are represented by black dots. 
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Figure 1. Boxplots showing the mRNA levels of (a) TOP2A; (b) MKI67; (c) CDKN2A/p16 in the different
diagnostic groups. Patients were grouped into three categories according to the cytological, histological,
and virological results. These categories included: (a) Negative (negative Pap test result and negative
high-risk human papillomavirus [HPV] test); (b) low-grade squamous intraepithelial lesion (LSIL) (Pap
test result of LSIL and biopsy showing anal intraepithelial neoplasia grade 1 [LSIL/AIN1]); and (c)
high-grade squamous intraepithelial lesion (HSIL) (patients with Pap test result of HSIL and biopsy
confirming HSIL/AIN2–3). The values shown are expressed as ∆∆Ct [(cycle threshold target-cycle
threshold reference sample) − (cycle threshold SiHa-cycle threshold reference SiHa)]. The black line
within the box represents the median; the whiskers represent the minimum and maximum values that
lie within 1.5 interquartile ranges from the end of the box. Values outside this range are represented by
black dots.
Table 2. mRNA levels of TOP2A, MKI67 and CDKN2A/p16 according to the diagnostic group.
Diagnosis
Negative LSIL HSIL p
TOP2A 4.07 (3.50–4.65) 4.00 (3.44–4.57) 3.19 (2.62–3.75) 0.051
MKI67 4.44 (3.81–5.07) 3.99 (3.52–4.46) 3.08 (2.54–3.61) 0.002
CDKN2A/p16 2.32 (1.85–2.80) 1.59 (1.13–2.06) 0.77 (0.33–1.21) <0.001
The values shown are expressed as ∆∆Ct [(cycle threshold target-cycle threshold reference sample) − (cycle threshold
SiHa-cycle threshold reference SiHa)] and 95% confidence interval. Patients were grouped into three categories
according to the cytological, histological, and virological results. These categories included: (a) negative (negative
Pap test result and negative high-risk human papillomavirus [HPV] test); (b) low-grade squamous intraepithelial
lesion (LSIL) (Pap test result of LSIL and biopsy showing anal intraepithelial neoplasia grade 1 [LSIL/AIN1]); and (c)
high-grade squamous intraep thelial lesio (HSIL) (pa ients with Pap test result of HSIL and biopsy confirming
HSIL/AIN2–3).
The ROC curves and the area under curve for the id ntification f patients with HSIL/AIN2–3
for the different biomarkers are shown in Figure 2 (A–C). The specificity and the cutoff values for the
identific ti n of HSIL/AIN2–3 for sensitivity e tablished at 70%, 80% and 90% is hown in Table 3.
The combination of the different biomarkers did not significantly improve the sensitivity and/or
specificity of the tests for the identification of patients with HSIL/AIN2–3.
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Figure 3 shows the HPV genotyping results in each diagnostic group. HPV16 was significantly 
more frequent in the HSIL group compared with the LSIL group (p = 0.003). Multiple HPV genotypes 
were found in 61.7% (63/199) of the samples studied. The prevalence of multiple infection was more 
frequent in the HSIL than in the LSIL group (56.7 [38/67] vs. 37.9%; [25/66]; p = 0.037).  
Figure 2. ROC curves and the area under curve for the identification of patients with HSIL/AIN2–3.
mRNA levels are presented as ∆∆Ct [(cycl threshold target-cycle threshold reference sample) − (cycle
threshold SiHa-cycle thr shold reference SiHa)]. T e values of the areas unde the ROC curve (AUC)
and the 95% confidence int rva s (95% CI) are present d. (a) TOP2A; (b) MKI67; (c) CDKN2A/p16.
Table 3. Cut-off values and specificity of TOP2A, MKI67 and CDKN2A/p16, for the diagnosis of
histologically confirmed high-grade squamous intraepithelial lesion (HSIL/AIN2–3) for sensitivity
established at 70%, 80% and 90%.
Sensitivity (%) Cut-Off Specificity (%) (95% CI)
TOP2A
70 4.50 44.7 (36.5–53.2)
80 6.01 20.7 (14.8–28.2)
90 7.11 11.4 (7.2–17.8)
MKI67
70 4.01 44.7 (36.5–53.2)
80 6.40 20.7 (14.8–28.2)
90 7.60 10.7 (6.6–16.9)
CDKN2A/p16
70 1.77 54.5 (36.5–53.2)
80 2.98 30.7 (23.7–38.8)
90 5.24 10.0 (6 0–16.1)
Figure 3 shows the HPV genotyping results in each diagnostic group. HPV16 was significantly
more frequent in the HSIL group compared with the LSIL group (p = 0.003). Multiple HPV genotypes
were found in 61.7% (63/199) of the samples studied. The prevalence of multiple infection was more
frequent in the HSIL than in the LSIL group (56.7 [38/67] vs. 37.9%; [25/66]; p = 0.037).
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Figure 3. u an papil o avirus (HPV) genotyping in the patients with anal lesions. The criteria for
the group of low-grade squamous intraepithelial esion (LSIL) were: Pap test result of LSIL and biopsy
showing anal intraepithelial neoplasia grade 1 [LSIL/AIN1]); the criteria for high-grade squamous
intraepithelial l i ere: Pap test result of HSIL and biopsy confirming HSIL/AIN2–3).
The results are presented in absolute numbers. Bars represent the percentage f t es ithin
the diagnostic group.
Table 4 and Figure 4 show the ∆∆Ct for the different biomarkers according to the HPV genotype.
The expression of the three biomarkers (TOP2A, MKI67 and CDKN2A/p16) was significantly higher in
samples which were positive for the HPV16 genotype compared with HPV18 and/or 45 or high-risk HPV
other than 16, 18 or 45. Patients with multiple infections showed a significantly higher expression of the
three biomarkers (TOP2A, MKI67 and CDKN2A/p16) compared with patients with a single infection.
∆∆Ct values in multiple and single infections were respectively 3.26 (95% confidence interval 2.60–3.92)
and 3.98 (95% confidence interval 3.61–4.35) for TOP2A (p = 0.044); 3.22 (95% confidence interval
2.66–3.79) and 4.12 (95% confidence interval 3.73–4.50) for MKI67 (p = 0.010) and 0.95 (95% confidence
interval 0.44–1.46) vs. 1.84 (95% confidence interval CI 1.52–2.16) for CDKN2A/p16 (p = 0.003).
Considering only multiple infections, although the expression of TOP2A, MKI67 and CDKN2A/p16
was higher in patients with multiple infections harboring HPV16 than in those not harboring this
genotype, the differences were only statistically significant for CDKN2A/p16.
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in samples which were positive for the HPV16 genotype compared w th HPV18 and/or 45 or high-
risk HPV other than 16, 18 or 45. Patients with multiple infections showed a significantly higher 
expression of the three biomarkers (TOP2A, MKI67 and CDKN2A/p16) compared with patients with
a single infection. ΔΔCt values in multiple and single infections were respectively 3.26 (95% 
confidence interval 2.60–3.92) and 3.98 (95% confidence interval 3.61–4.35) for TOP2A (p = 0.044); 3.22
(95% confidence interval 2.66–3.79) and 4.12 (95% confidence interval 3.73–4.50) for MKI67 (p = 0.010) 
and 0.95 (95% confidence interval 0.44–1.46) vs. 1.84 (95% confidence interval CI 1.52–2.16) for 
CDKN2A/p16 (p = 0.003). Considering l  ultiple infections, although the expression of TOP2A,
MKI67 and CDKN2A/p16 was higher i ients with multiple infections harboring HPV16 than in 
those not harboring this genotype, t  differences wer  only statistically significa t for 
(a)
Figure 4. Cont.
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 HPV16 HPV18 or 45  High-Risk HPV (non 16/18/45) Negative p 
TOP2A 2.99 (2.23–3.75) 4.20 (3.24–5.15) 3.82 (3.24–4.40) 4.12 (3.63–4.62) 0.040 
MKI67 3.17 (2.54–3.80) 3.61 (2.43–4.78) 3.70 (3.13–4.26) 4.40 (3.87–4.94) 0.020 
CDKN2A/p16 0.74 (0.21–1.26) 2.05 (0.95–3.16) 1.26 (0.76–1.76) 2.20 (1.77–2.62) <0.001
4. Discussion 
This is the first study evaluating the mRNA expression of host-cell genes involved in anal HPV-
associated carcinogenesis in men who have sex with men living with HIV. Our results show that this 
evaluation may be feasible in anal liquid-based cytology samples in a clinical setting. Thus, molecular 
Figure 4. Boxplots of the levels of (a) TOP2A; (b) MKI67; (c) CDKN2A/p16 according to the HPV
genotype. The values shown are ∆∆Ct [(cycle threshold target-cycle threshold reference sample) −
(cycle threshold SiHa-cycle threshold reference SiHa)]. The black line within the box represents the
median; the whiskers represent the minimum and maximum values that lie within 1.5 interquartile
ranges from the end of the box. Values outside this range are represented by black dots.
Table 4. mRNA levels of TOP2A, MKI67 and CDKN2A/p16 according to the HPV genotype. The values
shown are ∆∆Ct [(cycle threshold target-cycle threshold reference sample) − (cycle threshold SiHa-cycle
threshold reference SiHa)] and 95% confidence interval.
HPV16 HPV18 or 45 High-Risk HPV(non 16/18/45) Negative p
TOP2A 2.99 (2.23–3.75) 4.20 (3.24–5.15) 3.82 (3.24–4.40) 4.12 (3.63–4.62) 0.040
MKI67 3.17 (2.54–3.80) 3.61 (2.43–4.78) 3.70 (3.13–4.26) 4.40 (3.87–4.94) 0.020
CDKN2A/p16 0.74 (0.21–1.26) 2.05 (0.95–3.16) 1.26 (0.76–1.76) 2.20 (1.77–2.62) <0.001
4. Discussion
This is the first study evaluating the mRNA expression of host-cell genes involved in anal
HPV-associated carcinogenesis in men who have sex with men living with HIV. Our results show
that this evaluation may be feasible in anal liquid-based cytology samples in a clinical setting. Thus,
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molecular assays designed to detect the mRNA of host-cell biomarkers in specimens preserved in
liquid-based cytology media may be a promising approach for HSIL/AIN2–3 detection.
The current screening options for anal lesions in men who have sex with men living with HIV
have shown not only poor reproducibility, but also limited sensitivity and specificity to detect anal
HSIL/AIN2–3 [1,29]. On the basis of World Health Organization recommendations, several European
guidelines have endorsed screening based on HPV testing rather than cytology for cervical cancer,
the most common HPV-associated neoplasia, which has many analogies with anal cancer. [30] However,
the utility of anal cancer screening based on HPV testing in populations at risk is limited due to its
poor specificity, since anal HPV infection is detected in over 80% of these individuals [7] [31,32].
In the present study, we evaluated the feasibility of mRNA detection and its possible usefulness
for HSIL/AIN2–3 detection. Due to the technical difficulties of the anal cytology samples, we initially
focused on the technical issues. Extraction of high-quality RNA is a prerequisite for the application of
RNA transcripts as biomarkers for clinical purposes [12,33]. Few reports have analyzed the value of
biomarkers from anal scrapes, which have been considered as being particularly challenging because
of the low quality (attributed to a low cell count and fecal contamination) of some samples [29].
Remarkably, in our study, almost 93% of the specimens had RNA of adequate quality, which could be
successfully analyzed. These reliable results might be related to the high accuracy of the storage and
sample processing, which are critical steps to ensure high-quality RNA and show that, when performed
and processed appropriately, anal cytology samples preserved in liquid-based cytology fixatives are
adequate for RNA evaluation. The satisfactory results obtained in the feasibility evaluation are in
keeping with previous studies performed in cervical cancer [12,34] and indicate that evaluate this
approach for anal cancer screening may be clinically interesting.
The biomarkers analyzed in this study have shown good reproducibility, sensitivity, and specificity
in other HPV-associated malignancies such as cervical cancer. A previous study performed by our
group suggested that the analysis of mRNA expression of the same host-cell genes analyzed in
this study (TOP2A, MKI67 and CDKN2A/p16) is not only feasible but also useful for the detection
of cervical HSIL/CIN2–3 [12]. In our previous study, TOP2A, MKI67 and CDKN2A/p16 showed
sensitivities of 97%, 93% and 75%, respectively for HSIL/CIN2–3 with a specificity of 54%, 56% and
78%, respectively. In contrast with the promising results observed in the cervix, these biomarkers have
shown suboptimal sensitivity and specificity for detecting HSIL/AIN2–3 in anal samples [31]. Indeed,
the specificity of the different biomarkers for a sensitivity of 70%, which could be considered as the
minimum value acceptable for screening purposes, was 44.7% for TOP2A and MKI67 and 54.5% for
CDKN2A/p16. Moreover, an increased sensitivity implied an important decrease in the specificity,
suggesting these biomarkers are not adequate for screening purposes or that, if they were used for
screening of HSIL/AIN2–3, additional tests would be required to improve sensitivity and specificity.
Unfortunately, the selection criteria of the present study, designed to evaluate the feasibility of mRNA
expression in anal samples, do not allow proper comparison of the accuracy to detect HSIL/CIN2–3
between different tests such as cytology or HPV testing or the combinations of tests
In the present study HPV16 was the most frequent genotype identified in anal precursors, and its
prevalence was significantly higher in HSIL/AIN2–3 compared with LSIL/AIN1. These results are in
keeping with previous reports showing that HPV16 is the most common genotype as an etiologic factor
in HSIL/AIN2–3 and anal cancer [1,11,35]. As in previous studies, in the present series HPV16 was
positive in about 60% of the HSIL/AIN2–3 lesions and HPV18 was found in 7.5% of the HSIL/AIN2–3
samples. [36,37]. It has been shown that the percentage of HPV16 and 18 genotypes increases with the
severity of the diseases, and it is particularly high in invasive cancers [38]. Thus, HPV16 and/or 18
genotyping alone or in combination with additional tests might also be useful within an anal cancer
screening strategy [29,39,40]. Multiple HPV infections are also commonly reported in the anal region.
Indeed, the number of HPV types has been strongly associated with increasing levels of histological
abnormality [41,42] which is consistent with the results of this study.
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In the present study, we observed that the mRNA expression of host-cell genes was particularly
high in HPV16-positive samples. No previous studies have evaluated the relationship between the
expression of host-cell genes and different HPV genotypes in cytological anal samples. Thus, this is the
first study to evaluate the relation between HPV genotypes and mRNA expression of host-cell genes in
anal cytological samples from men having sex with men with HIV and SIL/AIN. Our results suggest
that this combination might be an interesting approach in risk-based management anal cancer screening,
simulating the approach that has recently been suggested for cervical screening [1]. Interestingly, the
mRNA expression of host-cell genes was higher in patients with multiple infections compared with
those with a single infection. In other HPV-related premalignant lesions, such as in the uterine cervix,
previous studies have shown the expression of the viral oncogene E6/E7 is higher in multiple HPV
infections compared with single infections [43]. However, there are no previous data about the effect of
multiple infections on the expression of host-cell genes in the anal canal in men having sex with men
living with HIV. Interestingly, in the subset of patients with multiple infections, those involving HPV16
showed higher mRNA expression of the host-cell genes than those without HPV16. Although the
differences were only significant for CDKN2A/p16, the trend was consistent for all the genes evaluated,
reinforcing the importance of HPV genotyping in anal cancer screening.
This study has some limitations. The possible changes in the levels of expression of the mRNA
of the biomarkers in patients with HPV infection not associated with intraepithelial lesions were
not evaluated. In our clinical setting, following the recommendations for anal cancer screening, this
particular high-risk population of men who have sex with men living with HIV with a negative cytology
does not undergo further examination with high-resolution anoscopy, and consequently, none of these
patients had histological confirmation of the negative result. Thus, the control group had to be recruited
based only on the cytology result, and we included the additional criteria of a negative HPV test to
ensure that the patients were truly negative and not false negative results of the cytology. Nevertheless,
the main aim of our study was to determine the feasibility of performing mRNA analysis of host-cells
in a standard clinical setting, which was independent of the patients selected. Another limitation is that
the presence and effect of low-risk HPV types could not be evaluated with the genotyping test used in
our study. However, although it has been suggested that low-risk HPV types may have a role in the
appearance of anal lesions, the risk of low-risk HPV infection in the development and progression of
anal premalignancies is clearly lower than the risk due to high-risk HPV infection [44,45].
In conclusion, we have shown that the determination of mRNA expression in anal liquid-based
cytology specimens is feasible. Further studies including a larger number of genes and patients
representing the complete picture found in an actual screening program are warranted to confirm that
strategies based on mRNA detection of cell biomarkers might have a role in the secondary prevention
of anal cancer.
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